Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 21, 2013, Pages 2909-2915

  Liang, H ^a   Zhang, L ^a   Xu, R ^a   Ju, Xiu Li ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Chemotherapy; Neuroblastoma; Survivin; YM155

Indexed keywords

CISPLATIN; MESSENGER RNA; SEPANTRONIUM BROMIDE; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; TUMOR REGRESSION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NAPHTHOQUINONES; NEUROBLASTOMA; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891772070     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. MARIS JM, HOGARTY MD, BAGATELL R, COHN SL. Neuroblastoma. Lancet 2007; 369: 2106-2120.
2. COHN SL, PEARSON AD, LONDON WB, MONCLAIR T, AMBROS PF, BRODEUR GM. INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-297.
3. AMBROSINI G, ADIDA C, ALTIERI DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
4. O'CONNOR DS, GROSSMAN D, PLESCIA J, LI F, ZHANG H, VILLA A, TOGNIN S, MARCHISIO PC, ALTIERI DC. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 2000; 97: 13103-13107.
5. GIODINI A, KALLIO MJ, WALL NR, GORBSKY GJ, TOGNIN S, MARCHISIO PC, SYMONS M, ALTIERI DC. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002; 62: 2462-2467.
6. FUKUDA S, PELUS LM. Regulation of the inhibitorofapoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001; 98: 2091-2100.
7. SARELA AI, MACADAM RC, FARMERY SM, MARKHAM AF, GUILLOU PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000; 46: 645-650.
8. MONZO M, ROSELL R, FELIP E, ASTUDILLO J, SÁNCHEZ JJ, MAESTRE J, MARTÍN C, FONT A, BARNADAS A, ABAD A. A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-2104.
9. TANAKA K, IWAMOTO S, GON G, NOHARA T, IWAMOTO M, TANIGAWA N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
10. ITO R, ASAMI S, MOTOHASHI S, OOTSUKA S, YAMAGUCHI Y, CHIN M, SHICHINO H, YOSHIDA Y, NEMOTO N, MUGISHIMA H, SUZUKI T. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull 2005; 28: 565-568.
11. AZUHATA T, SCOTT D, TAKAMIZAWA S, WEN J, DAVIDOFF A, FUKUZAWA M, SANDLER A. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 2001; 36: 1785-1791.
12. SHANKAR SL, MANI S, O'GUIN KN, KANDIMALLA ER, AGRAWAL S, SHAFIT-ZAGARDO B. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 2001; 79: 426-436.
13. LAMERS F, VAN DER PLOEG I, SCHILD L, EBUS ME, KOSTER J, HANSEN BR, KOCH T, VERSTEEG R, CARON HN, MOLENAAR JJ. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer 2011; 18: 657-668.
14. HOSSAIN MM, BANIK NL, RAY SK. Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells. Exp Cell Res 2012; 318: 1597-610.
15. CHANDELE A, PRASAD V, JAGTAP JC, SHUKLA R, SHASTRY PR. Upregulation of survivin in G2/M cells and inhibition of caspase-9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 2004; 6: 29-40.
16. NAKAHARA T, KITA A, YAMANAKA K, MORI M, AMINO N, TAKEUCHI M, TOMINAGA F, HATAKEYAMA S, KINOYAMA I, MATSUHISA A, KUDOH M, SASAMATA M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
17. KUMAR B, YADAV A, LANG JC, CIPOLLA MJ, SCHMITT AC, ARRADAZA N, TEKNOS TN, KUMAR P. YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels. Mol Cancer Ther 2012; 11: 9 1988-1998.
18. BRODEUR GM, MARIS JM. Principles and practice of pediatric oncology. 5 edition. Philadelphia: J B Lippincott Company 2006; pp. 933-970.
19. SATOH T, OKAMOTO I, MIYAZAKI M, MORINAGA R, TSUYA A, HASEGAWA Y, TERASHIMA M, UEDA S, FUKUOKA M, ARIYOSHI Y, SAITO T, MASUDA N, WATANABE H, TAGUCHI T, KAKIHARA T, AOYAMA Y, HASHIMOTO Y, NAKAGAWA K. Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors. Clin Cancer Res 2009; 15: 3872-3880.